Current Cardiovascular Drugs
Springer Science & Business Media, Jan 4, 2005 - Medical - 384 pages
This fourth edition of Current Cardiovascular Drugs is designed to provide an updated practical compendium of current knowledge regarding cardiovascular drug therapy in a concise, easily readable format. The book is organized into chapters by drug class, and details the pharmacologic characteristics of specific treatment entities. The clinical efficacy and limitations of the various drug therapies are discussed using supportive reference material from the most authoritative sources and published clinical trials. The book is for practicing physicians, physician's assistants, pharmacists, nurse practitioners, nurses, and residents.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
ACE inhibitors acid acute adjustment is required ADVERSE EFFECTS agents amiodarone angina antiarrhythmic antihypertensive artery aspirin atrial fibrillation benefits vs risk beta-blockers Bioavailability blockers bradycardia breast milk BRIEF INDICATIONS cardiac cardiovascular cholesterol cholestyramine clinical CoNTRAINDICATIONS coronary decrease digoxin diltiazem disease diuretics dizziness dosage adjustment dose with caution dose with frequent DRUG INTERACTIONS drug is excreted Duration of action edema Effect of food efficacy Elimination half-life established Elderly excreted in breast frequent monitoring Usual Frishman WH Groups Race heart failure heart rate heparin Hepatic impairment hypertension hypotension increase the effect/toxicity infusion initial dose intravenous liver lovastatin lower dose Metabolism metabolites mg once daily mg/d monitoring Usual dose myocardial infarction nausea Onset of action oral OVERDOSE PATIENT INFORMATION Peak effect PHARMACODYNAMICS Duration PHARMACOKINETICS AND PHARMACODYNAMICS platelet Pregnancy Protein binding receptor reduced Renal impairment safety and effectiveness side effects SPECIAL Groups Race tablets tachycardia therapy thiazide treatment trial verapamil Volume of distribution warfarin